Replies to post #33716 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

NWBO can make DCVax-L lysate from large gauge needle biopsies and/or vacuum biopsy. There was a discussion a while back regarding how small of a sample can be used these days, and I provided a link to the sample size available from these techniques. It may and probably should take more than one biopsy from different tumors within the same patient, because of tumor diversity and mutation.

Personally, I think DCVax-Direct is the best solution, but the above technique would provide sufficient sample for the combinational therapy if DCVax-L were to be used in combo with CI. However, I brought up L this time since we may find that NWBO wants to further establish DCVax-Direct's efficacy and safety independently of CIs for a longer period of time before attempting combinations with CIs. Whereas, DCVax-L has nothing to fear regarding any issues of possible safety being confounded from CIs to its decade and a half of extraordinary safety.

[RRRichmond]

Gentlemen and ladies (of course); I am really fascinated with the possibilities of a "surprise" cooperative trial With DCVax. As most of you are aware, my technical knowledge is limited and I often rely on many of you to provide the explanations in terms I can understand.

Giving the characteristics of DCVAX therapies; and those of other companies, I would like to ask,

1) What is the best possible cancer(s) to target, from the standpoint of a more effective therapy, in combination.

2) What company and what product do you see as having the best potential therapy?

3) Could you explain whether Direct or "L" is more likely to be the first used in a combination trial?

4) What would a combination trial do for each of the participants?